These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 10491434)

  • 1. Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.
    Yarbrough WG; Buckmire RA; Bessho M; Liu ET
    J Natl Cancer Inst; 1999 Sep; 91(18):1569-74. PubMed ID: 10491434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure of human cyclin-dependent kinase inhibitor p19INK4d: comparison to known ankyrin-repeat-containing structures and implications for the dysfunction of tumor suppressor p16INK4a.
    Baumgartner R; Fernandez-Catalan C; Winoto A; Huber R; Engh RA; Holak TA
    Structure; 1998 Oct; 6(10):1279-90. PubMed ID: 9782052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Requirement of cyclin E-Cdk2 inhibition in p16(INK4a)-mediated growth suppression.
    Jiang H; Chou HS; Zhu L
    Mol Cell Biol; 1998 Sep; 18(9):5284-90. PubMed ID: 9710613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
    Fåhraeus R; Laín S; Ball KL; Lane DP
    Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of functional elements of p18INK4C essential for binding and inhibition of cyclin-dependent kinase (CDK) 4 and CDK6.
    Noh SJ; Li Y; Xiong Y; Guan KL
    Cancer Res; 1999 Feb; 59(3):558-64. PubMed ID: 9973200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with oncogenic mutations.
    Cammett TJ; Luo L; Peng ZY
    J Mol Biol; 2003 Mar; 327(1):285-97. PubMed ID: 12614625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural characterization of the tumor suppressor p16, an ankyrin-like repeat protein.
    Boice JA; Fairman R
    Protein Sci; 1996 Sep; 5(9):1776-84. PubMed ID: 8880901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural consequences of tumor-derived mutations in p16INK4a probed by limited proteolysis.
    Zhang B; Peng ZY
    Biochemistry; 2002 May; 41(20):6293-302. PubMed ID: 12009890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding.
    Becker TM; Rizos H; Kefford RF; Mann GJ
    Clin Cancer Res; 2001 Oct; 7(10):3282-8. PubMed ID: 11595726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of CDK7-carboxyl-terminal domain kinase activity by the tumor suppressor p16(INK4A) contributes to cell cycle regulation.
    Nishiwaki E; Turner SL; Harju S; Miyazaki S; Kashiwagi M; Koh J; Serizawa H
    Mol Cell Biol; 2000 Oct; 20(20):7726-34. PubMed ID: 11003668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Several noncontiguous domains of CDK4 are involved in binding to the P16 tumor suppressor protein.
    Ceha HM; Nasser I; Medema RH; Slebos RJ
    Biochem Biophys Res Commun; 1998 Aug; 249(2):550-5. PubMed ID: 9712735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An NF-kappaB-specific inhibitor, IkappaBalpha, binds to and inhibits cyclin-dependent kinase 4.
    Li J; Joo SH; Tsai MD
    Biochemistry; 2003 Nov; 42(46):13476-83. PubMed ID: 14621993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p16INK4A mediates cyclin dependent kinase 4 and 6 inhibition in senescent prostatic epithelial cells.
    Sandhu C; Peehl DM; Slingerland J
    Cancer Res; 2000 May; 60(10):2616-22. PubMed ID: 10825132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A.
    Fåhraeus R; Paramio JM; Ball KL; Laín S; Lane DP
    Curr Biol; 1996 Jan; 6(1):84-91. PubMed ID: 8805225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts.
    Alcorta DA; Xiong Y; Phelps D; Hannon G; Beach D; Barrett JC
    Proc Natl Acad Sci U S A; 1996 Nov; 93(24):13742-7. PubMed ID: 8943005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent deregulation of p16 and the p16/G1 cell cycle-regulatory pathway in neuroblastoma.
    Diccianni MB; Omura-Minamisawa M; Batova A; Le T; Bridgeman L; Yu AL
    Int J Cancer; 1999 Jan; 80(1):145-54. PubMed ID: 9935245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a.
    Russo AA; Tong L; Lee JO; Jeffrey PD; Pavletich NP
    Nature; 1998 Sep; 395(6699):237-43. PubMed ID: 9751050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural analysis of the inhibition of Cdk4 and Cdk6 by p16(INK4a) through molecular dynamics simulations.
    Villacañas O; Pérez JJ; Rubio-Martínez J
    J Biomol Struct Dyn; 2002 Dec; 20(3):347-58. PubMed ID: 12437373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.
    McKenzie HA; Fung C; Becker TM; Irvine M; Mann GJ; Kefford RF; Rizos H
    Hum Mutat; 2010 Jun; 31(6):692-701. PubMed ID: 20340136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity.
    Lilischkis R; Sarcevic B; Kennedy C; Warlters A; Sutherland RL
    Int J Cancer; 1996 Apr; 66(2):249-54. PubMed ID: 8603820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.